- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07354178
Estudo do Hemostático de Trombina à Base de Colagénio para o Controlo de Hemorragias em Cirurgia Espinal
Ensaio Clínico Randomizado para Avaliar a Hemostasia pela Aplicação de Hemostático à Base de Colagénio Contendo Trombina em Cirurgia da Coluna Vertebral
This clinical trial evaluated the effectiveness and safety of a collagen-based hemostatic agent containing thrombin in patients undergoing spinal surgery. The study compared this investigational product with an existing hemostatic agent to assess whether it performed equally well in controlling surgical bleeding. Patients with spinal stenosis, tumors, or trauma who required spinal surgery were enrolled. The hemostat was applied intraoperatively when grade 3 bleeding was observed. The study assessed hemostatic performance and safety of the product when used during surgery.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This was a randomized, single-blind, active-controlled clinical trial designed to assess the non-inferiority of a collagen-based thrombin-containing topical hemostat (CollaStat) compared to an existing hemostatic agent (Floseal) in patients undergoing spinal surgery. The investigational product was designed to be highly biocompatible to reduce adverse effects in case of in-body residue after application. Patients who underwent spinal surgery due to spinal stenosis, tumors, or trauma were enrolled and randomized in a 1:1 ratio. The hemostatic products were applied intraoperatively at bleeding sites classified as grade 3. For grade 4 or 5 bleeding, temporary hemostatic procedures were performed first to reduce bleeding intensity before applying the assigned hemostat. The study's primary endpoint was the hemostasis success rate, defined as the achievement of hemostasis within 1 minute, 2 minutes, 3 minutes, 6 minutes, and 10 minutes of product application without additional intervention. Secondary outcomes included time to hemostasis, number of hemostatic units used per patient, volume of postoperative surgical drainage, length of hospital stay, incidence of intraoperative rebleeding, occurrence of postoperative hematoma or surgical site infection, and overall hemostatic effect assessed across all treated bleeding sites.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Gangnam-gu
-
Seoul, Gangnam-gu, Coréia do Sul, 06273
- Gangnam Severance Hospital
-
-
Giheung-gu
-
Yongin-si, Giheung-gu, Coréia do Sul, 16995
- Yongin Severance Hospital
-
-
Seodaemun-gu
-
Seoul, Seodaemun-gu, Coréia do Sul, 03722
- Severance Hospital, Yonsei University Health Syetem
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- An individual who has voluntarily signed the written consent form for participating in the research as a trial subject
- Patients aged 20 or older
- Patients who are able to participate throughout the entire clinical trial period
- Patient scheduled to have spinal surgery due to spinal stenosis, spinal tumor, injury, etc.
- Patients for whom hemostasis is difficult to achieve using standard procedures
- Patients with grade 3 or higher bleeding * Grade 4 or 5 bleeding is reduced to grade 3 by normal procedures (compression, sutures, electrosurgical scalpel, etc.).
Exclusion Criteria:
- Pregnant women or those planning to become pregnant within 1 month after application of the collagen-based hemostat
- Individuals with hypersensitivity to bovine-, porcine-, or animal-derived materials
- Individuals deemed inappropriate for participation by the investigators
- Patients who are using treatments that may affect the test results
- Patients with active infections at the surgical site
- Patients with contraindications to the use of local hemostatic materials
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Study Group
Group applied with CollaStat® |
Clinical subjects are enrolled after the clinical investigator confirms that there are bleeding sites where hemostasis by normal procedures (compression, suturing, electrosurgical scalpel, etc.) is ineffective or difficult to perform. To arrest intraoperative bleeding, the study group is treated with Dalim Tissen's CollaStat® and compressed with general gauze. |
|
Comparador Ativo: Control Group
Group applied with Floseal® |
Clinical subjects are enrolled after the clinical investigator confirms that there are bleeding sites where hemostasis by normal procedures (compression, suturing, electrosurgical scalpel, etc.) is ineffective or difficult to perform. To arrest intraoperative bleeding, the control group is treated with Baxter's Floseal® and compressed with general gauze |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hemostasis success rate
Prazo: Hemostasis at the first bleeding site is confirmed at 1 minute, 2 minutes, 3 minutes, 6 minutes, and 10 minutes
|
After applying the haemostatic agent to the bleeding site, gentle compression is performed using surgical gauze. After lifting the gauze and washing off the excess hemostatic agent, check if hemostasis is maintained |
Hemostasis at the first bleeding site is confirmed at 1 minute, 2 minutes, 3 minutes, 6 minutes, and 10 minutes
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Presença de re-hemorragia no local da hemorragia índice
Prazo: Desde a primeira aplicação (Visita 2; dia da cirurgia) até ao fim do acompanhamento (até 8 semanas após a cirurgia)
|
Desde a primeira aplicação (Visita 2; dia da cirurgia) até ao fim do acompanhamento (até 8 semanas após a cirurgia)
|
|
|
Time to hemostasis
Prazo: Intraoperation
|
Record the time point when hemostasis is achieved. |
Intraoperation
|
|
Number of hemostats used
Prazo: Intraoperation
|
Record the number of hemostats used until hemostasis. |
Intraoperation
|
|
Length of Hospital Stay
Prazo: From the date of surgical operation (Visit 2) until the date of hospital discharge, assessed up to 1 week (±3 days) after surgery
|
Length of hospital stay is defined as the number of days from the date of surgery (Visit 2) to the date of hospital discharge. |
From the date of surgical operation (Visit 2) until the date of hospital discharge, assessed up to 1 week (±3 days) after surgery
|
|
Incidence of adverse events
Prazo: From first application of the investigational medical device through end of follow-up (up to 8 weeks post-surgery)
|
Adverse events include hematoma and infection. |
From first application of the investigational medical device through end of follow-up (up to 8 weeks post-surgery)
|
|
Drain amount
Prazo: 3 days after surgery
|
Record the drain amount until the 3rd postoperative day. |
3 days after surgery
|
|
Evaluation of Handling Characteristics (as Assessed by the Surgeon)
Prazo: Intraoperative
|
Hemostasis will be assessed intraoperatively at all treated bleeding sites after application of the investigational product (IP). Only the assigned IP should be used for the same patient. |
Intraoperative
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças ósseas
- Doenças musculoesqueléticas
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Ferimentos e Lesões
- Processos Patológicos
- Neoplasias por local
- Neoplasias
- Hemorragia
- Doenças da coluna vertebral
- Neoplasias do Sistema Nervoso
- Neoplasias do Sistema Nervoso Central
- Doenças da Medula Espinhal
- Complicações Intraoperatórias
- Lesões nas costas
- Condições Patológicas, Sinais e Sintomas
- Estenose espinal
- Neoplasias da Medula Espinhal
- Perda de Sangue, Cirúrgica
- Lesões na coluna
Outros números de identificação do estudo
- DRT-CS01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Undecided. The plan for sharing individual participant data has not yet been determined.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .